GlassScriptPhysician profile
Amy Lynette Hazel
NPI 1568468965
$62,728.08
in general payments reported to CMS, 2019-2025
40 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,654 · 2022: $13K · 2023: $13K · 2024: $19K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $17K · Food and Beverage: $8,374 · Travel and Lodging: $7,447 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,501 · Consulting Fee: $4,125 · Education: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $16,500.00 |
| Food and Beverage | $8,374.43 |
| Travel and Lodging | $7,446.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,501.00 |
| Consulting Fee | $4,125.00 |
| Education | $701.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $32,203.25 | 2021-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $7,555.60 | 2021-2025 | |
| Akebia Therapeutics INC | $7,178.37 | 2021-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $5,204.53 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,636.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $921.30 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $900.06 | 2021-2025 | Tavneos, Parsabiv, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $821.84 | 2021-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $726.92 | 2022-2024 | Rayaldee |
| Daiichi Sankyo INC. | $657.69 | 2021-2025 | Injectafer |
| Vifor Pharma, INC. | $339.41 | 2021-2024 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $287.13 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $264.52 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $245.15 | 2021-2024 | Jesduvroq |
| Alexion Pharmaceuticals, INC. | $193.21 | 2021-2025 | Ultomiris |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $157.67 | 2021-2025 | Acthar, Terlivaz |
| Medtronic, INC. | $147.24 | 2025 | Symplicity G3 |
| Xeris Pharmaceuticals, INC. | $145.57 | 2022-2025 | Keveyis |
| Horizon Therapeutics Plc | $126.01 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.82 | 2023-2024 | Jardiance |
| Ardelyx, INC. | $118.32 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $105.90 | 2024-2025 | Wegovy, Ozempic |
| Atricure, INC. | $104.94 | 2023 | |
| Genzyme Corporation | $93.76 | 2025 | |
| Ani Pharmaceuticals, INC. | $91.47 | 2023-2024 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $56.19 | 2023-2025 | Filspari |
| Gilead Sciences, INC. | $48.65 | 2024 | |
| Abbott Laboratories | $34.00 | 2021 | |
| Amag Pharmaceuticals, INC. | $32.08 | 2021 | |
| Nxstage Medical, INC. | $25.32 | 2021-2022 | |
| Renalytix Ai, INC. | $22.76 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Corcept Therapeutics | $20.98 | 2025 | Korlym |
| Apellis Pharmaceuticals, INC. | $19.32 | 2025 | |
| Shield Therapeutics INC | $19.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2021 | |
| Vantive US Healthcare LLC | $17.05 | 2025 | Renal - Pd |
| Lilly USA, LLC | $16.95 | 2023 | Jardiance |
| Kci USA, INC. | $16.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.